Skip to main content
. 2018 Jan 1;9(2):263–268. doi: 10.7150/jca.20059

Figure 1.

Figure 1

Cancer vaccines can be designed in a way to target immunogenic neo-antigens, even clonal neo-antigens that are encoded by driver mutations. Furthermore, cancer vaccines can be put to application in combination with immune checkpoint inhibitors.